{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:27Z","timestamp":1788416007123,"version":"build-2803163510"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epithelioid malignant peritoneal mesothelioma (EMPM) is a rare and aggressive malignancy of serosal origin. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is generally reserved for carefully selected patients in whom adequate cytoreduction appears feasible, while evidence supporting systemic immunotherapy remains limited for patients with unresectable disease or those unable to tolerate intensive treatment. Iparomlimab and tuvonralimab (QL1706) is a fixed-ratio anti-PD-1\/anti-CTLA-4 MabPair formulation that has shown preliminary antitumor activity in several advanced solid tumors, but clinical experience in EMPM remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We retrospectively describe three patients with EMPM diagnosed through integrated clinicopathologic assessment who received QL1706 either as monotherapy or in combination with an antiangiogenic agent. Treatment response was assessed by the treating team on serial computed tomography (CT) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as the evaluation framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Case 1 was a 53-year-old woman with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 10. Diffuse peritoneal disease persisted after surgery and three sessions of postoperative catheter-based hyperthermic intraperitoneal chemotherapy. QL1706 plus bevacizumab subsequently produced stable disease with symptomatic improvement for approximately 7 months. Case 2 was an 89-year-old man with a PD-L1 CPS of 0 who was considered unsuitable for surgery or intensive chemotherapy. QL1706 plus dose-reduced lenvatinib achieved a partial response that remained ongoing for more than 10 months. Case 3 was a 70-year-old man with a PD-L1 CPS of 55 and pre-existing nephrotic syndrome. QL1706 monotherapy induced a rapid partial response, but treatment was discontinued because of worsening proteinuria and edema; the disease subsequently progressed, with a new intracranial lesion radiologically suspicious for metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QL1706-based therapy achieved disease control in all three patients with EMPM who had limited conventional treatment options, including a durable response in an elderly patient with PD-L1-negative disease and rapid tumor regression with QL1706 monotherapy. The contrasting clinical courses suggest that overall benefit depends not only on tumor sensitivity but also on the accompanying treatment strategy and baseline organ function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1914733","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:27Z","timestamp":1788412947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhijin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, School of The First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehe","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, School of The First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, School of The First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, School of The First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35868","article-title":"Consensus guideline for the management of peritoneal mesothelioma","volume":"131","author":"Brown","year":"2025","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27947","article-title":"Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of diffuse Malignant peritoneal mesothelioma: a GRADE approach for evidence evaluation and recommendation","volume":"131","author":"Kusamura","year":"2025","journal-title":"J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced Malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced Malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1410322","article-title":"Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature","volume":"14","author":"Reveneau","year":"2024","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116066","article-title":"Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: a French experience","volume":"231","author":"Smolenschi","year":"2025","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD-1\/CTLA-4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102396","article-title":"Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1\/CTLA-4 dual blocker in advanced solid tumors: a phase 1\/1b study","volume":"6","author":"Ma","year":"2025","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01731-x","article-title":"QL1706 (anti-PD-1 IgG4\/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study","volume":"9","author":"Huang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:28Z","timestamp":1788412948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":12,"alternative-id":["10.3389\/fonc.2026.1914733"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1914733","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1914733"}}